Eli Lilly’s stock has been on a tear, driven by positive trial results for its Alzheimer’s drug and progress with its promising obesity drug pipeline.
You are here: Home / Eli Lilly raises full-year guidance as Mounjaro, other drugs drive second-quarter profit up 85%